This investment will support state-of-the-art health research for Canada’s leading diseases, including cancer, diabetes, dementia, muscular dystrophy and universal donor blood.
Catégorie : Communiqué de presse
As a member of BIOTECanada’s network, GlycoNet aims to mobilize glycomics research into tangible and sustainable innovation for Canadians.
The collaborative project is partnered with CQDM, Simon Fraser University, Amgen, Merck, and Servier.
Genetic disease research has benefitted substantially from the study of glycomics, which relates to the functions of glycans, or sugar, in biological systems
The Network will commit $1.8 million in glycomics to support made-in-Canada health innovations and build a sustainable national bioeconomy
Project funded through CQDM Quantum Leap program with support from Merck and GlycoNet will exploit new drug development platform
$1.3 million in funding to support new sugar research to tackle unmet needs in national healthcare
The made-in-Canada technology is revolutionizing the cryopreservation of cell and tissues.
Pediatric cardiologist Lori West is one of six researchers from the University of Alberta receiving $2.8 million in federal funding for “exceptional opportunities” in fight against the pandemic.
Discovering antiviral and anticancer drugs will soon be faster and cheaper thanks to new research from GlycoNet Investigator Dr. Robert Britton at Simon Fraser University and his international team.